NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Evelo Biosciences, Inc. (NASDAQ:EVLO), ADMA Biologics Inc (NASDAQ:ADMA), Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Pingtan Marine Enterprise Ltd. (NASDAQ:PME), Rosetta Stone (NYSE:RST), and Williams Companies, Inc. (NYSE:WMB), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
EVLO DOWNLOAD: http://Fundamental-Markets.com/register/?so=EVLO
ADMA DOWNLOAD: http://Fundamental-Markets.com/register/?so=ADMA
KPTI DOWNLOAD: http://Fundamental-Markets.com/register/?so=KPTI
PME DOWNLOAD: http://Fundamental-Markets.com/register/?so=PME
RST DOWNLOAD: http://Fundamental-Markets.com/register/?so=RST
WMB DOWNLOAD: http://Fundamental-Markets.com/register/?so=WMB
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Evelo Biosciences, Inc. (NASDAQ:EVLO), ADMA Biologics Inc (NASDAQ:ADMA), Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Pingtan Marine Enterprise Ltd. (NASDAQ:PME), Rosetta Stone (NYSE:RST), and Williams Companies, Inc. (NYSE:WMB) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 9th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
EVELO BIOSCIENCES, INC. (EVLO) REPORT OVERVIEW
Evelo Biosciences' Recent Financial Performance
Analysts expect earnings to be released on February 7th, 2019. The report will be for the fiscal period ending December 31st, 2018. The estimated EPS forecast for the next fiscal year is -$2.04 and is expected to report on February 7th, 2019.
To read the full Evelo Biosciences, Inc. (EVLO) report, download it here: http://Fundamental-Markets.com/register/?so=EVLO
-----------------------------------------
ADMA BIOLOGICS INC (ADMA) REPORT OVERVIEW
ADMA Biologics' Recent Financial Performance
For the three months ended June 30th, 2018 vs June 30th, 2017, ADMA Biologics reported revenue of $4.66MM vs $3.40MM (up 36.98%) and analysts estimated basic earnings per share -$0.35 vs -$0.55. For the twelve months ended December 31st, 2017 vs December 31st, 2016, ADMA Biologics reported revenue of $22.76MM vs $10.66MM (up 113.49%) and analysts estimated basic earnings per share -$1.91 vs -$1.61. Analysts expect earnings to be released on March 4th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.24. The estimated EPS forecast for the next fiscal year is -$0.50 and is expected to report on March 4th, 2019.
To read the full ADMA Biologics Inc (ADMA) report, download it here: http://Fundamental-Markets.com/register/?so=ADMA
-----------------------------------------
KARYOPHARM THERAPEUTICS INC. (KPTI) REPORT OVERVIEW
Karyopharm Therapeutics' Recent Financial Performance
For the twelve months ended December 31st, 2017 vs December 31st, 2016, Karyopharm Therapeutics reported revenue of $1.61MM vs $0.15MM (up 942.21%) and analysts estimated basic earnings per share -$2.81 vs -$2.92. Analysts expect earnings to be released on March 21st, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.80. The estimated EPS forecast for the next fiscal year is -$3.18 and is expected to report on March 21st, 2019.
To read the full Karyopharm Therapeutics Inc. (KPTI) report, download it here: http://Fundamental-Markets.com/register/?so=KPTI
-----------------------------------------
PINGTAN MARINE ENTERPRISE LTD. (PME) REPORT OVERVIEW
Pingtan Marine Enterprise's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Pingtan Marine Enterprise reported revenue of $14.69MM vs $5.46MM (up 168.83%) and basic earnings per share $0.16 vs $0.08 (up 100.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Pingtan Marine Enterprise reported revenue of $63.21MM vs $20.54MM (up 207.73%) and analysts estimated basic earnings per share $0.38 vs -$0.17. Analysts expect earnings to be released on March 13th, 2019. The report will be for the fiscal period ending December 31st, 2018.
To read the full Pingtan Marine Enterprise Ltd. (PME) report, download it here: http://Fundamental-Markets.com/register/?so=PME
-----------------------------------------
ROSETTA STONE (RST) REPORT OVERVIEW
Rosetta Stone's Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Rosetta Stone reported revenue of $42.75MM vs $46.21MM (down 7.48%) and analysts estimated basic earnings per share -$0.31 vs -$0.14. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Rosetta Stone reported revenue of $184.59MM vs $194.09MM (down 4.89%) and analysts estimated basic earnings per share -$0.07 vs -$1.25. Analysts expect earnings to be released on March 6th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.14. The estimated EPS forecast for the next fiscal year is -$0.71 and is expected to report on March 6th, 2019.
To read the full Rosetta Stone (RST) report, download it here: http://Fundamental-Markets.com/register/?so=RST
-----------------------------------------
WILLIAMS COMPANIES, INC. (WMB) REPORT OVERVIEW
Williams Companies' Recent Financial Performance
For the three months ended September 30th, 2018 vs September 30th, 2017, Williams Companies reported revenue of $2,303.00MM vs $1,891.00MM (up 21.79%) and analysts estimated basic earnings per share $0.13 vs $0.04 (up 225.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Williams Companies reported revenue of $8,031.00MM vs $7,499.00MM (up 7.09%) and analysts estimated basic earnings per share $2.63 vs -$0.57. Analysts expect earnings to be released on February 13th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.20. The estimated EPS forecast for the next fiscal year is $0.95 and is expected to report on February 13th, 2019.
To read the full Williams Companies, Inc. (WMB) report, download it here: http://Fundamental-Markets.com/register/?so=WMB
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.